Skip to main content
SpringerLink
Log in

A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer, an Eastern Cooperative Oncology Group trial. Cancer 54:970–977

    Article  PubMed  CAS  Google Scholar 

  2. Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1(8442):1006–1010

    Article  PubMed  CAS  Google Scholar 

  3. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1998) Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma: A prospective randomized trial. Cancer 62:479–483

    Article  Google Scholar 

  4. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN (1993) Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4:327–332

    PubMed  CAS  Google Scholar 

  5. Neuman MG (2001) Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci 38(2):109–166

    Article  PubMed  CAS  Google Scholar 

  6. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M (2005) Apoptosis in liver diseases—detection and therapeutic applications. Med Sci Monit 11:RA337–RA345

    PubMed  CAS  Google Scholar 

  7. Chiu CT, Yeh TS, Hsu JS, Chen MF (2003) Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 48(4):670–676

    Article  PubMed  CAS  Google Scholar 

  8. Cheng SC, Luo D, Xie Y (2001) Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 25(3):261–265

    Article  PubMed  CAS  Google Scholar 

  9. Luo D, Cheng SC, Xie H, Xie Y (1999) Chemosensitivity of human HCC cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20(6):331–340

    Article  PubMed  CAS  Google Scholar 

  10. Ma S, Lee TK, Zheng BT, Chan KW (2007) CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (in press)

  11. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891–2902

    PubMed  CAS  Google Scholar 

  12. Lopes de Menezes DE, Mayer LD (2001) Combination of bcl-2 antisense oligodeoxynucleotide (G3139), p-glycoprotein inhibitor (PSC833) and liposomal doxorubicin can suppress the growth of drug-resistant human breast cancer xenografts in SCID mice “abstract”. Proc Ann Meet Am Assoc Cancer Res 42:A2018

    Google Scholar 

Download references

Conflict of interest statement

None declared.

Author information

Authors and Affiliations

  1. Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada

    J. J. Knox, X. E. Chen, R. Feld, M. Nematollahi, R. Cheiken, G. Pond & M. Moore

  2. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA

    J. A. Zwiebel

  3. The British Columbia Cancer Agency, Vancouver, British Columbia, Canada

    S. Gill

  4. Medical Oncology, Princess Margaret Hospital—University Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada

    J. J. Knox

Authors
  1. J. J. Knox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. E. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Feld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Nematollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Cheiken
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Pond
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. A. Zwiebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. J. Knox.

Additional information

This work is supported by an NIH/NCI Phase II Consortium NO-1 Grant 1710701.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knox, J.J., Chen, X.E., Feld, R. et al. A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs 26, 193–194 (2008). https://doi.org/10.1007/s10637-007-9104-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-007-9104-1

Keywords

Search

Navigation